Background ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve
survival and reduce morbidity in patients with acute myocardial infarction and evidence of …

Patients with acute myocardial infarction and evidence of heart failure or left ventricular
dysfunction during the acute phase have an excessive mortality risk. Therapy with …

Proven cardiovascular benefit from angiotensin-converting enzyme (ACE) inhibition is a
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce
mortality and cardiovascular morbidity among patients with myocardial infarction …

puted placebo analysis). 21 In this analysis, losartan 50 mg once daily could not be shown
to be better than placebo. Concern that the dose of losartan was too low in this trial (and in …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …

Background The ELITE study showed an association between the angiotensin II antagonist
losartan and an unexpected survival benefit in elderly heart-failure patients, compared with …

Objectives: We attempted to compare the effect of an angiotensin-converting enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events. Background …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

Background. Long-term administration of angiotensin-converting—enzyme (ACE) inhibitors
has been shown to improve survival in patients with symptomatic left ventricular failure and …